XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
0.740
+0.012 (1.63%)
Mar 9, 2026, 3:26 PM EDT - Market open
XTL Biopharmaceuticals Revenue
XTL Biopharmaceuticals had revenue of $258.50K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $968.00K. In the year 2024, XTL Biopharmaceuticals had annual revenue of $451.00K.
Revenue (ttm)
$968.00K
Revenue Growth
n/a
P/S Ratio
6.65
Revenue / Employee
$96,800
Employees
10
Market Cap
6.43M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| Can-Fite BioPharma | 560.00K |
| Aprea Therapeutics | 488.24K |
| Creative Medical Technology Holdings | 6.00K |
XTLB News
- 9 days ago - XTL Biopharmaceuticals (XTLB) Faces Nasdaq Delisting Threat - GuruFocus
- 9 days ago - XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing - GlobeNewsWire
- 5 weeks ago - XTL Biopharmaceuticals Aims to Acquire Stake in NeuroNOS from Beyond Air (XAIR) - GuruFocus
- 5 weeks ago - XTL Update on Recent Developments - GlobeNewsWire
- 6 weeks ago - XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - GlobeNewsWire
- 7 weeks ago - XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - GlobeNewsWire
- 7 weeks ago - XTL Biopharmaceuticals To Acquire 85% Stake In NeuroNOS Ltd For $32.5 Mln - Nasdaq
- 7 weeks ago - Beyond Air (XAIR) Moves NeuroNOS to XTL Biopharmaceuticals Through Acquisition Deal - GuruFocus